The World Health Organization approves two new treatments for (Covid-19) patients
On Friday, the World Health Organization approved two drugs to treat people with (Covid-19) to be added to a group of available methods in addition to vaccines, to stave off the risk of severe symptoms and death from the virus.
This comes at a time when hospitals around the world are overwhelmed with patients with the mutated “Omicron”, while the organization had previously expected that half of the European population would be infected by March.
In their recommendation, which was published in the British Medical Journal “BMJ”, the organization’s experts said that the arthritis drug baricitinib, used with corticosteroids to treat Covid patients with severe or critical symptoms, improved the survival rate and reduced the need for devices. Ventilator.
Experts have also recommended treatment with the synthetic antibody sotrovimab for patients with non-serious COVID-19 who are at risk of hospitalization, such as the elderly and people with immunodeficiency or chronic diseases such as diabetes.
The benefits of sutromivab for people who are not at risk of hospitalization were considered insignificant, and the WHO said that its efficacy against new mutations such as “Omicron” “remains uncertain”.
So far, three other treatments for Covid patients have received WHO approval, starting with corticosteroids for people with severe symptoms in September 2020.
Corticosteroids are low cost and widely used to treat infections that usually accompany acute cases.
The two drugs used to treat osteoarthritis patients, tocilizumab and sarilumab, recommended by the World Health Organization in July, belong to a family called “interleukin-6 antagonists” (or IL-6 antagonists) and, like corticosteroids, fight the immune system’s wildness that appears to be the source of severe forms of covid
According to the guidelines, “when the two are available, a choice is made between them based on issues such as cost and clinical experience.”
The WHO approved the treatment with the synthetic antibody Regeneron in September, and guidelines say sotrofimab can be used in the same group of patients.
WHO recommendations regarding the treatment of Covid are updated regularly based on new data from clinical trials.
Khartoum (Kush News)